Trials / Completed
CompletedNCT00658671
A Dose-Escalation Study of ENMD-2076 Administered Orally to Patients With Advanced Cancer
An Open-Label, Dose-Escalation, Safety, and Pharmacokinetic Study of ENMD-2076 Administered Orally to Patients With Advanced Cancer
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 67 (actual)
- Sponsor
- CASI Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A dose-escalation trial designed to assess the safety and tolerability of treatment with ENMD-2076 administered orally over a range of doses in patients with advanced cancer that is refractory to current treatment or for which no curative therapy exists.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ENMD-2076 | Capsules, daily dosing in 28 day cycles |
Timeline
- Start date
- 2008-04-01
- Primary completion
- 2010-12-01
- Completion
- 2012-06-01
- First posted
- 2008-04-15
- Last updated
- 2023-02-06
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00658671. Inclusion in this directory is not an endorsement.